White paper – From PROTACs to DACs: How targeted protein degraders are breaking rules and boundaries in drug design
- grebner0
- Jun 27
- 1 min read
Protein degraders, such as proteolysis-targeting chimeras (PROTACs) and other chimeric targeted protein degraders, represent a highly promising class of molecules for the development of new drugs against a variety of diseases like cancer or neurodegenerative diseases. These innovative compounds are capable of targeting disease-related proteins that are often deemed “undruggable” by conventional approaches.
A new white paper from our PROXIDRUGS partner Revvity, published at c&en discusses the multidisciplinary expertise and close collaboration required for addressing unique challenge when developing such complex molecules. It highlights why collaborative efforts are essential and gives an overview of the biggest breakthroughs in the fields and first clinical trials, calling for combined partnerships and strategic investments so protein degraders can meet critical medical needs.
